PMID- 16034519
OWN - NLM
STAT- MEDLINE
DCOM- 20060428
LR  - 20221207
IS  - 0167-6997 (Print)
IS  - 0167-6997 (Linking)
VI  - 23
IP  - 6
DP  - 2005 Dec
TI  - Activity of carboplatin in patients with advanced non-small cell lung cancer 
      pre-treated with a non-platinum combination.
PG  - 597-601
AB  - To assess the efficacy of carboplatin when used as a single agent in patients 
      with advanced non small cell lung cancer (NSCLC) and who are refractory to 
      chemotherapy with a non-platinum combination, we recruited patients (n=40) NSCLC 
      patients, 36 of whom were males, with an overall median age of 59 years (range 
      39-79) and Karnofsky Performance Status of 70% (range 60-90%). At baseline, the 
      patients had a median of one disease site (range 1-3) and had received a median 
      of one prior regimen (range 1-2). Carboplatin was administered (i.v.; AUC=6) 
      every 3 weeks until disease progression or non-acceptable toxicity was reached. 
      In total 169 cycles were administered (median 4 cycles/patient; range 1-8). Main 
      toxicities were grade 2-3 anemia and grade 4 thrombocytopenia (22.5% of 
      patients). Overall clinical response rate was 10% (4 partial responses); 26 
      patients (65%) had stable disease and 8 (20%) had disease progression. Median 
      time to progression and median survival time were 90 and 187 days, respectively. 
      One year survival rate was 13%. We conclude that carboplatin shows minimal 
      toxicity with a discrete anti-tumor activity in patients with NSCLC and who are 
      refractory to non-platinum combinations.
FAU - Esteban-Gonzalez, Emilio
AU  - Esteban-Gonzalez E
AD  - Medical Oncology Department, Hospital Central de Asturias, Oviedo, Spain.
FAU - Fernandez, Yolanda
AU  - Fernandez Y
FAU - Villanueva, Noemi
AU  - Villanueva N
FAU - Fra, Joaquin
AU  - Fra J
FAU - Muniz, Isabel
AU  - Muniz I
FAU - Palacio, Isabel
AU  - Palacio I
FAU - Vieitez, Jose M
AU  - Vieitez JM
FAU - Una, Esther
AU  - Una E
FAU - Mareque, Beatriz
AU  - Mareque B
FAU - Lacave, Angel J
AU  - Lacave AJ
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - BG3F62OND5 (Carboplatin)
RN  - Q6C979R91Y (Vinorelbine)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antimetabolites, Antineoplastic/administration & dosage
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Antineoplastic Agents, Phytogenic/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Vinblastine/administration & dosage/analogs & derivatives
MH  - Vinorelbine
MH  - Gemcitabine
EDAT- 2005/07/22 09:00
MHDA- 2006/04/29 09:00
CRDT- 2005/07/22 09:00
PHST- 2005/07/22 09:00 [pubmed]
PHST- 2006/04/29 09:00 [medline]
PHST- 2005/07/22 09:00 [entrez]
AID - 10.1007/s10637-005-0556-x [doi]
PST - ppublish
SO  - Invest New Drugs. 2005 Dec;23(6):597-601. doi: 10.1007/s10637-005-0556-x.